Pasireotide-induced hyperglycemia in a patient with Cushing's disease : Potential use of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist for treatment
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd..
Pasireotide improves hypercortisolemia and induces hyperglycemia via somatostatin receptor type-5 stimulation. GLP-1RA and SGLT2 inhibitor potentially help regulate hyperglycemia in patients with Cushing's disease, especially after pasireotide administration.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Clinical case reports - 8(2020), 12 vom: 17. Dez., Seite 2613-2618 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shikata, Masato [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Revised 30.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/ccr3.3230 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319280942 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319280942 | ||
| 003 | DE-627 | ||
| 005 | 20240330234833.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ccr3.3230 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1356.xml |
| 035 | |a (DE-627)NLM319280942 | ||
| 035 | |a (NLM)33363790 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shikata, Masato |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pasireotide-induced hyperglycemia in a patient with Cushing's disease |b Potential use of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist for treatment |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. | ||
| 520 | |a Pasireotide improves hypercortisolemia and induces hyperglycemia via somatostatin receptor type-5 stimulation. GLP-1RA and SGLT2 inhibitor potentially help regulate hyperglycemia in patients with Cushing's disease, especially after pasireotide administration | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Cushing's disease | |
| 650 | 4 | |a diabetes mellitus | |
| 650 | 4 | |a glucagon‐like peptide‐1 receptor agonist | |
| 650 | 4 | |a pasireotide | |
| 650 | 4 | |a sodium‐glucose cotransporter 2 inhibitor | |
| 700 | 1 | |a Ashida, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Goto, Yuka |e verfasserin |4 aut | |
| 700 | 1 | |a Nagayama, Ayako |e verfasserin |4 aut | |
| 700 | 1 | |a Iwata, Shimpei |e verfasserin |4 aut | |
| 700 | 1 | |a Yano, Mamiko |e verfasserin |4 aut | |
| 700 | 1 | |a Hasuzawa, Nao |e verfasserin |4 aut | |
| 700 | 1 | |a Hara, Kento |e verfasserin |4 aut | |
| 700 | 1 | |a Mawatari, Kazutoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Sakata, Kiyohiko |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuruta, Munehisa |e verfasserin |4 aut | |
| 700 | 1 | |a Wada, Nobuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Nomura, Masatoshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical case reports |d 2013 |g 8(2020), 12 vom: 17. Dez., Seite 2613-2618 |w (DE-627)NLM234405864 |x 2050-0904 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2020 |g number:12 |g day:17 |g month:12 |g pages:2613-2618 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ccr3.3230 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2020 |e 12 |b 17 |c 12 |h 2613-2618 | ||